Investor relations

Investor relations

Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.

NYSE: MRK
May 6, 2021 10:56 pm ET
Delayed at least 20 minutes

Latest news, events & financials

May 6, 2021

Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program

May 6, 2021

Merck and Eisai Receive Priority Review From FDA for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma

May 5, 2021

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

View all

May 25, 2021

Other

Merck & Co., Inc. 2021 Annual Meeting of Shareholders

Add to Calendar

June 07, 2021

Merck & Co., Inc. Oncology Event at ASCO 2021

Add to Calendar

July 29, 2021

Earnings

Merck & Co., Inc. Q2 2021 Earnings Call

Add to Calendar

October 28, 2021

Earnings

Merck & Co., Inc. Q3 2021 Earnings Call

Add to Calendar

View all

1Q21 Merck Earnings Announcement
PDF

1Q21 Merck Other Financial Disclosures
PDF

View all

Organon & Co. Investor Day

See full agenda

Our pipeline shows our relentless pursuit of the next breakthrough.

Explore our pipeline

Phase II programs

Phase III programs

Under review

Our leadership

Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.

Leadership

Corporate responsibility

Supporting the future of our business and the health and well-being of patients, people and communities around the world.

Explore our CR report

Download ESG Progress Report

We're led by our science

We follow the science to our next breakthrough, leaving no stone unturned.

View our stories

Innovation

Our first-quarter 2021 financial results

Merck announced first-quarter sales of $12.1 billion, in-line with first-quarter 2020. Excluding the impact from foreign exchange, sales declined 1%. The company anticipates full-year 2021 revenue range to be between $51.8 billion and $53.8 billion, including a positive impact from foreign exchange of less than 2%. Take a look at the infographic below for more […]

Next: Our first-quarter 2021 financial results